GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Return-on-Tangible-Equity

Egyptian International Pharmaceutical Investments (CAI:PHAR) Return-on-Tangible-Equity : 24.45% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Egyptian International Pharmaceutical Investments's annualized net income for the quarter that ended in Dec. 2023 was E£1,018 Mil. Egyptian International Pharmaceutical Investments's average shareholder tangible equity for the quarter that ended in Dec. 2023 was E£4,166 Mil. Therefore, Egyptian International Pharmaceutical Investments's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 24.45%.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity or its related term are showing as below:

CAI:PHAR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.8   Med: 22.36   Max: 29.62
Current: 22.36

During the past 13 years, Egyptian International Pharmaceutical Investments's highest Return-on-Tangible-Equity was 29.62%. The lowest was 16.80%. And the median was 22.36%.

CAI:PHAR's Return-on-Tangible-Equity is ranked better than
84.99% of 933 companies
in the Drug Manufacturers industry
Industry Median: 6.31 vs CAI:PHAR: 22.36

Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.45 16.82 16.80 20.74 21.98

Egyptian International Pharmaceutical Investments Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.06 22.72 32.19 11.20 24.45

Competitive Comparison of Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity falls into.



Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Calculation

Egyptian International Pharmaceutical Investments's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=823.306/( (3237.767+4255.106 )/ 2 )
=823.306/3746.4365
=21.98 %

Egyptian International Pharmaceutical Investments's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=1018.4/( (4075.975+4255.106)/ 2 )
=1018.4/4165.5405
=24.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Headlines